Moderna, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +15

Moderna stock: Goldman Sachs lifts target for Moderna stock to USD 137.00

Analyst upgrade AI-generated analysis

πŸ“ˆ Goldman Sachs lifted its price target for Moderna from USD 120.00 to USD 137.00 on October 15, 2026.

πŸ“Š Moderna reported Q2 2026 revenue of USD 145.00 million, up 2.00% year-over-year.

πŸ’° The company's net loss narrowed to USD 782.00 million in the second quarter of 2026.

πŸ—“οΈ Moderna will host an investor webcast on October 24, 2026, to discuss upcoming clinical results.

πŸ”¬ The company plans to present Phase 3 melanoma data at the European Society for Medical Oncology congress.

πŸ’Ή Moderna's market capitalization stood at USD 87.0 billion as of October 16, 2026.

πŸ“‰ The stock traded at a P/E ratio of minus 27.32, reflecting its current loss-making status.

πŸ“ˆ Shares closed up 0.17% on the Xetra exchange at EUR 192.12 on October 19, 2026.

Bullish Signals
  • Goldman Sachs increased its price target for Moderna from USD 120.00 to USD 137.00, signaling continued analyst interest in the company's long-term prospects.
  • Revenue grew by 2.00% year-over-year to USD 145.00 million in the second quarter of 2026, demonstrating top-line growth despite current profitability challenges.
Risk Factors
  • Moderna reported a net loss of USD 782.00 million for the second quarter of 2026, indicating the company is still operating at a significant deficit.
  • The stock trades at a negative P/E ratio of minus 27.32, reflecting investor caution regarding the company's current earnings trajectory and cash burn.
Full Analysis
Goldman Sachs raised its price target for Moderna Inc. (MRNA) from USD 120.00 to USD 137.00 on October 15, 2026, while maintaining a Neutral rating. This adjustment reflects the company's ongoing clinical progress and market positioning within the biotechnology sector, specifically ahead of upcoming data presentations. Moderna reported second-quarter 2026 revenue of USD 145.00 million, representing a 2.00% increase from the prior-year quarter. Despite this growth, the company recorded a net loss of USD 782.00 million, which improved by USD 43.00 million compared to the previous year, indicating a narrowing deficit as it advances its pipeline. The company is preparing to present Phase 3 melanoma data at the European Society for Medical Oncology congress on October 24, 2026, alongside an investor webcast. These events are critical milestones that investors will monitor closely to assess the potential commercial viability of its oncology portfolio.